Neovasc (Neovasc) Asset Impairment Charge : $0.00 Mil (TTM As of Dec. 2022)

View and export this data going back to 2008. Start your Free Trial

What is Neovasc Asset Impairment Charge?

Neovasc's Asset Impairment Charge for the three months ended in Dec. 2022 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

Neovasc Asset Impairment Charge Historical Data

The historical data trend for Neovasc's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neovasc Asset Impairment Charge Chart

Neovasc Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Asset Impairment Charge

Get a 7-Day Free Trial

0.49

0.14

0.59

Neovasc Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Neovasc Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Neovasc Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Neovasc's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Neovasc (Neovasc) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neovasc Inc (NAS:NVCN) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

13562 Maycrest Way, Suite 5138, Richmond, BC, CAN, V6V 2J7

Website

https://www.neovasc.com

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.